SLDB Stock Analysis: Buy, Sell, or Hold?
SLDB - Solid Biosciences Inc. Common Stock
$6.92
-0.71 (-9.31%)
▼
5d:
-4.81%
30d:
-17.52%
90d:
+11.79%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 21, 2026
2d
Smart Money Distribution
SLDB is up 7.9% this week, but smart money is buying puts. Top strike: $6 2026-06-18 with 67 OI. Put ratio: 68% View Scanner →
Strength: 5.8/10
Get Alerted When SLDB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SLDB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SLDB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SLDB is currently trading at $6.92, which is considered oversold relative to its 30-day fair value range of $7.23 to $8.25.
Technical Outlook: Technically, SLDB is in a strong uptrend. The price is currently testing key support at $6.76. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.3% recently.
Market Sentiment: SLDB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $17.08 (+146.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SLDB is in a strong uptrend. The price is currently testing key support at $6.76. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.3% recently.
Market Sentiment: SLDB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $17.08 (+146.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.23 -
$8.25
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.3%)
- BULLISH: Trading 146.8% below Wall St target ($17.08)
Trading Range Analysis
30-Day Trading Range
$7.23 -
$8.25
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.76
Resistance Level
$7.93
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.11
Wall Street Target
$17.08
(+146.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 18, 2026 7:32 AM ET
Data refreshes hourly during market hours. Next update: 8:32 AM
Data refreshes hourly during market hours. Next update: 8:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLDB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
David T Howton
SELL
7469 shares
2026-02-18
Ilan Ganot
SELL
2658 shares
2026-02-18
Jessie Hanrahan
SELL
4134 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 59 HOLD |
